2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, (CAR)-T Cell Therapies, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Genomics, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Thrombocytopenias, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, Research, APL, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Pregnant, Animal Model
PAPER

1297 Marstacimab for acquired hemophilia A: A case report

Wenjing Gu, MD, Wei Liu2, Lei Zhang, MD3
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: Marstacimab is a monoclonal antibody that targets tissue factor pathway inhibitor (TFPI) and restores hemostatic balance by enhancing thrombin generation. Previous animal studies have shown that marstacimab enhances platelet aggregation and fibrin formation in factor VIII (FVIII)-deficient hemophilia A mice and, independently of FVIII, reduces blood loss and restores hemostasis after bleeding. These findings suggest that marstacimab may represent a novel hemostatic treatment option for acquired hemophilia A (AHA).
Case Presentation: A 65-year-old female was admitted with a history of recurrent ecchymoses involving the left extremities, accompanied by localized swelling, pain, and restricted mobility, for more than 20 days. Her symptoms had worsened over the preceding 5 days, and she developed sudden syncope and melena. Laboratory testing showed a hemoglobin level of 56 g/L, a platelet count of 286 × 10^9/L, an activated partial thromboplastin time of 59.8 s, FVIII activity <1.0%, a peak FVIII inhibitor titer of 125.72 Bethesda units (BU), von Willebrand factor antigen 215.8%, von Willebrand factor activity 263.5%, and factor IX activity 123.4%. A diagnosis of AHA was established. Initial hemostatic therapy comprised recombinant activated factor VII (rFVIIa) administered at 90 μg/kg every 4 hours, prothrombin complex concentrate (PCC) at 50IU/kg/day, and antifibrinolytic agents administered with an appropriate interval from PCC. However, FVIII activity did not increase appreciably, and the gastrointestinal bleeding remained inadequately controlled. In the setting of this hemostatic challenge, marstacimab was initiated concurrently with rFVIIa at a subcutaneous dose of 300 mg once weekly for 3 weeks, followed by a single reduced dose of 150 mg before discontinuation. One week after initiation of marstacimab, gastrointestinal bleeding improved markedly, accompanied by a substantial increase in hemoglobin to 65 g/L. Hemoglobin further increased to 89 g/L after 2 weeks and reached 105 g/L after 3 weeks of treatment. Inhibitor eradication therapy consisted of a single 600-mg dose of rituximab and cyclophosphamide 0.2 g every other day. Methylprednisolone 40 mg/day was added after the gastrointestinal bleeding had improved. Follow-up testing to date has shown  an FVIII activity of 86.9% and a decrease in the FVIII inhibitor titer to 0.77 BU. Ongoing follow-up is continuing.
Discussion: To our knowledge, this is the first reported case of marstacimab use in AHA. The combination of marstacimab and rFVIIa provided effective hemostasis in this older patient with AHA complicated by a high-titer FVIII inhibitor and severe gastrointestinal and multisite soft-tissue bleeding, in conjunction with inhibitor eradication therapy. Marstacimab may offer a novel therapeutic option for patients with very low FVIII activity or high-titer FVIII inhibitors. Its subcutaneous route of administration may also reduce the burden of venous access and provide sustained protection against bleeding while awaiting the onset of effect of immunosuppressive therapy.

Wenjing Gu, MD: No relevant conflicts of interest to declare.